Luaterra

Luaterra is a biotechnology company focused on developing next-generation radiopharmaceuticals for the treatment of cancer. The company utilizes a targeted radioligand therapy platform to deliver therapeutic isotopes directly to tumor cells, aiming to improve efficacy and safety for patients with solid tumors. Their lead program, LT-002, is a small molecule radioligand targeting Prostate-Specific Membrane Antigen (PSMA) for the treatment of prostate cancer. Luaterra's leadership team includes pioneers from Endocyte and Point Biopharma, bringing significant expertise in ligand discovery and radiochemistry. The company is headquartered in West Lafayette, Indiana, and is supported by leading life science venture capital firms.